Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20902165 | 0.88 | MEN1 (0.49) | TACR1CNR2TSHRMEN1KMT2A | |
| SCHEMBL4159626 | 0.88 | HSD11B1 (0.56) | TACR1RORCHDAC2HDAC1JAK2 | |
| SCHEMBL2427295 | 0.85 | TACR1 (0.51) | TACR1RORCHDAC2HDAC1JAK2 | |
| SCHEMBL4704330 | 0.85 | TACR1 (0.43) | TACR1RORCHDAC2HDAC1JAK2 | |
| SCHEMBL3327426 | 0.84 | TACR1 (0.50) | TACR1RORCHDAC2HDAC1JAK2 | |
| SCHEMBL1206023 | 0.81 | TACR1 (0.53) | TACR1RORCTSHRALOX15ATM | |
| SCHEMBL2519801 | 0.81 | RORC (0.52) | TACR1RORCHDAC2HDAC1JAK2 | |
| SCHEMBL18618022 | 0.81 | RORC (0.49) | TACR1RORCHDAC2HDAC1 | |
| SCHEMBL31382020 | 0.80 | TSHR (0.51) | RORCHDAC2HDAC1JAK2JAK1 | |
| SCHEMBL3264110 | 0.79 | RORC (0.49) | TACR1RORCHDAC2HDAC1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262041-A1 | Beta-Lactams for Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1689737-B1 | BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1689737-A1 | BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049600-A1 | BETA-LACTAMS FOR TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262041-A1 | Beta-Lactams for Treatment of Cns Disorders | SLC7A1, TPH1, CHRNA10 | TACR1 96/4885RORC 4384/4885HDAC2 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.